ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $771,189 | +15.9% | 8,850 | +21.4% | 0.04% | +20.0% |
Q2 2023 | $665,322 | +8.6% | 7,288 | -5.1% | 0.04% | -2.8% |
Q1 2023 | $612,394 | -31.4% | 7,677 | +0.1% | 0.04% | -34.5% |
Q4 2022 | $892,637 | -28.1% | 7,672 | -23.0% | 0.06% | -38.2% |
Q3 2022 | $1,242,000 | +84.5% | 9,959 | +26.6% | 0.09% | +81.6% |
Q2 2022 | $673,000 | +0.6% | 7,866 | +1.1% | 0.05% | -3.9% |
Q1 2022 | $669,000 | -40.6% | 7,781 | -15.8% | 0.05% | -36.2% |
Q4 2021 | $1,126,000 | -19.8% | 9,246 | +2.0% | 0.08% | -18.4% |
Q3 2021 | $1,404,000 | -32.8% | 9,061 | -51.1% | 0.10% | +25.6% |
Q2 2021 | $2,090,000 | +38.3% | 18,546 | +66.5% | 0.08% | -37.6% |
Q1 2021 | $1,511,000 | +20.0% | 11,141 | +42.1% | 0.12% | +5.0% |
Q4 2020 | $1,259,000 | +128.9% | 7,839 | +137.4% | 0.12% | +83.1% |
Q3 2020 | $550,000 | – | 3,302 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |